Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 27;13(3):66-71.
doi: 10.4331/wjbc.v13.i3.66.

Progesterone in gender-affirming therapy of trans women

Affiliations
Review

Progesterone in gender-affirming therapy of trans women

Charalampos Milionis et al. World J Biol Chem. .

Abstract

Progesterone is an endogenous steroid hormone with an important role for the physiology of the female reproductive system and the mammary gland. It has additional significant actions in other tissues, such as the cardiovascular system, the central nervous system, and bones. The present article explores potential clinical implications from the addition of bioidentical progesterone to gender-affirming treatment of trans women. For this purpose, it provides an overview of the physiological action of progesterone in target tissues and speculates on possible benefits for gender transitioning. Progesterone is expected to exert moderate anti-androgen action through suppression of the hypothalamic-pituitary-gonadal axis and inhibition of the conversion of testosterone to dihydrotestosterone. It may also contribute to breast maturation. In the long-term, progesterone could prevent bone loss and protect cardiovascular health. The potential benefits are mainly inferred by extrapolating evidence from biological actions in cisgender women and medical assumptions and hence, clinicians need to be cautious when applying these data into practice. Further research is needed to ascertain the efficacy and safety of progesterone in current hormonal regimens.

Keywords: Breast; Gender dysphoria; Human; Progesterone; Transgender persons.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors state that they have no conflict of interest to report.

Similar articles

Cited by

References

    1. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32:81–151. - PMC - PubMed
    1. MacKenzie SM, van Kralingen JC, Davies E. Regulation of Aldosterone Secretion. Vitam Horm. 2019;109:241–263. - PubMed
    1. Garg D, Ng SSM, Baig KM, Driggers P, Segars J. Progesterone-Mediated Non-Classical Signaling. Trends Endocrinol Metab. 2017;28:656–668. - PubMed
    1. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev. 1997;18:502–519. - PubMed
    1. Taraborrelli S. Physiology, production and action of progesterone. Acta Obstet Gynecol Scand. 2015;94 Suppl 161:8–16. - PubMed